ULURU Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on ULURU's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2018 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses BreakdownBeta
How ULURU makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 18 | 1 | -2 | 2 | 0 |
| 30 Jun 18 | 1 | -2 | 2 | 0 |
| 31 Mar 18 | 1 | -2 | 2 | 0 |
| 31 Dec 17 | 1 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -4 | 1 | 0 |
| 30 Jun 17 | 0 | -4 | 1 | 0 |
| 31 Mar 17 | 1 | -4 | 1 | 0 |
| 31 Dec 16 | 0 | -4 | 1 | 0 |
| 30 Sep 16 | 1 | -2 | 1 | 1 |
| 30 Jun 16 | 1 | -2 | 1 | 1 |
| 31 Mar 16 | 1 | -3 | 2 | 1 |
| 31 Dec 15 | 1 | -3 | 2 | 1 |
| 30 Sep 15 | 1 | -2 | 2 | 1 |
| 30 Jun 15 | 1 | -2 | 2 | 1 |
| 31 Mar 15 | 1 | -2 | 2 | 1 |
| 31 Dec 14 | 1 | -2 | 2 | 1 |
| 30 Sep 14 | 1 | -3 | 2 | 1 |
| 30 Jun 14 | 1 | -3 | 2 | 1 |
| 31 Mar 14 | 0 | -3 | 1 | 1 |
| 31 Dec 13 | 0 | -3 | 1 | 1 |
| 30 Sep 13 | 0 | -3 | 1 | 1 |
| 30 Jun 13 | 0 | -3 | 1 | 1 |
| 31 Mar 13 | 0 | -3 | 2 | 1 |
| 31 Dec 12 | 0 | -4 | 2 | 1 |
| 30 Sep 12 | 0 | -3 | 2 | 1 |
| 30 Jun 12 | 0 | -4 | 2 | 1 |
Quality Earnings: Insufficient data to determine if ULUR has high quality earnings.
Growing Profit Margin: Insufficient data to determine if ULUR's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ULUR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare ULUR's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if ULUR's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: ULUR has a negative Return on Equity (0%), as it is currently unprofitable.